Table 2. Patient characteristics in Feasibility (Stage 2) studies.
| Study I | Study II | Study III | Study IV | PoC Study | |
| Number of patients/samples | 128/128 | 320/320 | 85/255* | 119/119** | 24/107* |
| Female, % | 82 | 80 | 91 | 77 | 75 |
| CCP+, % | 63 | 62 | 62 | 61 | n/a |
| RF+, % | 83 | 83 | 64 | 97 | n/a |
| Smoker, % | n/a | 13 | 4 | 22 | n/a |
| Methotrexate, % | 53 | 61 | 48 | 64 | 100 |
| Non-biologic DMARDs, % | 69 | 76 | 64 | 81 | 100 |
| Biologics, % | 65 | 53 | 43 | 50 | 50 |
| Corticosteroids, % | 24 | 27 | 27 | 33 | n/a |
| Age, mean±SD (min,max) | 60±13 | 59±14 | 59±13 | 60±14 | 56±13 |
| DAS28-CRP, median (IQR) | 5.8 (4.7–6.5) | 4.0 (2.9–5.3) | 3.8 (2.7–5.0) | 5.2 (4.1–6.2) | 3.3 (2.2–4.4) |
| TJC28, median (IQR) | 12 (4.8–20) | 2.0 (0–8.3) | 7.0 (2.0–14) | 8.0 (3.0–15) | 3.0 (0.0–8.0) |
| SJC28, median (IQR) | 16 (12–21) | 6.5 (2–13) | 2.0 (0.0–10) | 14 (8.0–20) | 4.0 (1.0–7.0) |
| CRP mg/L, median (IQR) | 14 (4.0–32) | 14 (5.1–45) | 14 (4.0–47) | 18 (6.9–47) | 25 (7.6–70) |
| PG, median (IQR) | 5.0 (2.9–7.0) | 2.5 (1.0–5.0) | 3.0 (1.0–5.0) | 5.0 (2.0–6.5) | n/a |
DMARD, disease-modifying anti-rheumatic drug; IQR, inter-quartile range.
*
For studies with multiple samples per patient, sex, age, and serological status (when available) statistics are based on unique patients. Other statistics are based on all samples.
**
All studies used independent patients and samples, except Study IV, which used a subset of Study II samples.